Theravance Biopharma Inc Forecast, price target & analysts
Theravance Biopharma Inc Target price 2026 - Analyst rating & recommendation
Theravance Biopharma Inc Classifications & Recommendation
Theravance Biopharma Inc Price Target
| Target Price | $17.34 |
| Price | $17.04 |
| Potential |
1.76%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Theravance Biopharma Inc 2027 .
The average Theravance Biopharma Inc target price is $17.34.
This is
1.76%
register free of charge
$19.95
17.08%
register free of charge
$17.17
0.76%
register free of charge
|
|
| A rating was issued by 11 analysts: 6 Analysts recommend Theravance Biopharma Inc to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Theravance Biopharma Inc stock has an average upside potential 2027 of
1.76%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 107.46 | 119.20 |
| 66.92% | 10.92% | |
| Net Margin | 98.55% | 115.45% |
| 212.45% | 17.15% |
8 Analysts have issued a sales forecast Theravance Biopharma Inc 2026 . The average Theravance Biopharma Inc sales estimate is
This results in the following potential growth metrics:
8 Theravance Biopharma Inc Analysts have issued a net profit forecast 2026. The average Theravance Biopharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.06 | 2.65 |
| 277.59% | 28.64% | |
| P/E | 6.43 | |
| EV/Sales | 4.45 |
8 Analysts have issued a Theravance Biopharma Inc forecast for earnings per share. The average Theravance Biopharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Theravance Biopharma Inc...
Current Theravance Biopharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jul 07 2026 |
| Jones Trading |
Locked
➜
Locked
|
Locked | Jun 29 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Jun 29 2026 |
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Apr 07 2026 |
| TD Cowen |
Locked
➜
Locked
|
Locked | Mar 23 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Mar 20 2026 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Mar 05 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jul 07 2026 |
|
Locked
Jones Trading:
Locked
➜
Locked
|
Jun 29 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Jun 29 2026 |
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Apr 07 2026 |
|
Locked
TD Cowen:
Locked
➜
Locked
|
Mar 23 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Mar 20 2026 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Mar 05 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
